PUBLISHER: DelveInsight | PRODUCT CODE: 1226564
PUBLISHER: DelveInsight | PRODUCT CODE: 1226564
"CAEL-101 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about CAEL-101 for AL Amyloidosis in the 7MM. A detailed picture of the CAEL-101 for AL Amyloidosis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the CAEL-101 for AL Amyloidosis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CAEL-101 market forecast, analysis for AL Amyloidosis in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in AL Amyloidosis.
CAEL-101 (previously known as 11-1F4) is a first-in-class, light chain fibril-reactive mAb (monoclonal antibody) being developed as targeted therapy by Caelum Biosciences. The therapy is designed to improve organ function by reducing or eliminating amyloid deposits in the tissues and organs of patients with AL amyloidosis. The antibody has a unique capability of binding to misfolded light chain proteins, especially to both kappa and lambda subtypes of amyloid proteins.
CAEL-101 has received Orphan Drug Designation from both the FDA and EMA as a therapy for patients with AL amyloidosis.
The company initiated Phase III clinical studies to treat AL amyloidosis patients. The Cardiac Amyloid Reaching for Extended Survival (CARES) clinical program includes two parallel Phase III studies-one in patients with Mayo stage IIIa disease and another in patients with Mayo stage IIIb disease. They will collectively enroll approximately 370 patients globally.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
CAEL-101 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of CAEL-101 in AL Amyloidosis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of CAEL-101 for AL Amyloidosis covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions